Locteron Triumphs in Phase 2 Hepatitis C Trial

[Guest guest]

Locteron Triumphs in Phase 2 Hepatitis C Trial

With dosing once every other week, a similar effectiveness as PEG-Intron and fewer side effects, Locteron's Phase 2B trial is successful.

Positive Results in Phase 2 Locteron Trial

Drug Discovery & Development - October 29, 2010

Biolex Therapeutics, Inc. announced positive efficacy, safety and tolerability results from its 72-week SELECT-2 Phase 2b dose-finding Phase 2b trial of Locteron, the company's lead product candidate for the treatment of hepatitis C. For each of the three Locteron doses tested in SELECT-2, the percentage of patients who maintained undetectable levels of virus at week 60 of the trial, 12 weeks after completion of 48 weeks of treatment (SVR12), were comparable with or exceeded the response rate for the PEG-Intron control. As a result of its controlled-release mechanism, Locteron was dosed half as frequently as PEG-Intron.

Continue reading this entire article:http://www.dddmag.com/news-Positive-Results-in-Phase-2-Locteron-Trial-102910.aspx

http://www.hepatitis-central.com/mt/archives/2010/11/locteron_triump.html